Intestinal imbalance in young people as a marker of chronic somatic diseases
https://doi.org/10.31146/1682-8658-ecg-200-4-153-159
Abstract
This review presents generalized data of modern Russian and foreign researchers on the relationship between the development of chronic diseases of the cardiovascular, respiratory, and digestive systems in adults and metabolic disorders with changes in the composition and metabolic activity of the intestinal microbiota. Particular attention was paid to the analysis of the results of studies of young people (from 18 to 35 years old), also in the article, as an eff ective comparison, data on children of adolescence and youth are given. The studied data are of scientifi c interest from the point of view of the search for new targets and treatment schemes for the prevention of somatic diseases and their therapy through the restoration of the ecosystem of the gastrointestinal tract.
About the Authors
V. M. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
Vyacheslav M. Chervinet., MD, PhD, Head of Department of Microbiology and Virology with the Cypse of Immunology
4, Sovetskaya St., Tver, 170100
Yu. V. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
Yuliya V. Chervinets, MD, PhD of Department of Microbiology and Virology with the Cypse of Immunology
4, Sovetskaya St., Tver, 170100
E. S. Kravchuk
Tver State Medical University
Russian Federation
Russian Federation
Elina S. Kravchuk, post-graduate student, Assistant of the Department of Microbiology and Virology with the Cypse of Immunology
4, Sovetskaya St., Tver, 170100
References
1. World Health Organization. Newsletters. Top 10 causes of death in the world 2020. Geneva. 2020, 2P. (in Russ.)
2. World health statistics 2018: monitoring health for the SDGs, sustainable developm. Geneva.2018; 100 P.
3. Health care in Russia. 2019: Statistical compendium. Moscow: Rosstat Publ., 2019, 170 р. (In Russ.)
4. Drapkina O. M., Shirobokikh O. E. Role of Gut Microbiota in the Pathogenesis of Cardiovascular Diseases and Metabolic Syndrome. Rational Pharmacotherapy in Cardiology. 2018;14(4):567–574. (In Russ.) doi: 10.20996/1819–6446–2018–14–4–567–574
5. Li J., Zhao F., Wang Y., et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017; 5(1):14.
6. Qi Y., Kim S., Richards E. M., et al. Gut Microbiota: Potential for a Unifying Hypothesis for Prevention and Treatment of Hypertension. Circ Res. 2017; 120(11):1724–6.
7. Marques F.Z., Mackay C. R., Kaye D. M. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018; 15(1): 20–32.
8. Juraschek S.P., Bower J. K., Selvin E., et al. Plasma lactate and incident hypertension in the atherosclerosis risk in communities study. Am. J. Hypertens.2015; 28: 216–24.
9. Gomez- Guzman M., Toral M., Romero M., et al. Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res. 2015; (59):2326–36.
10. Bhaskaran K., dos- Santos- Silva I., Leon D. A., et al. Association of BMI with overall and cause- specifi c mortality: a population- based cohort study of 3·6 million adults in the UK. Lancet.2018; 6(12): 944–953.
11. Hou Y.P., He Q. Q., Ouyang H. M.. et al. Human gut microbiota associated with obesity in Chinese children and adolescents. Biomed Res Int. 2017: 7585989.
12. Schwiertz A., Taras D., Schafer K., et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010; 18(1): 190–5.
13. Novikova E. A., Bairova T. A. Obesity: Ethnic and Regional Diff erences in the Diet and Gut Microbiota (Review). Acta Biomedica Scientifi ca. 2019;4(1):19–25. (In Russ.) doi: 10.29413/ABS.2019–4.1.3
14. DepommierC., EverardA., DruartC., et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med.2019; 25(7): 1096–1103.
15. Tang W.H., Kitai T., Hazen S. L., et al. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017;120(7):1183–1196. doi: 10.1161/CIRCRESAHA.117.309715
16. Ryazantsev S.V., Krivopalov A. A., Eremin S. A. Features of nonspecifi c prevention and treatment of patients with exacerbation of chronic tonsillitis. RMJ. 2017. № 23. P. 1688–1694. (In Russ.)
17. Rybak N. A., Cyrkunov V. M., Rybak R. F. [Microbiocenosis of the palatine tonsils in chronic tonsillitis]. Healthcare. 2014;12: 2–7. (In Russ.)
18. Jensen A., H. Fago- Olsen, C. H. Sorensen Molecular Mapping to Species Level of the Tonsillar Crypt Microbiota Associated with Health and Recurrent Tonsillitis. PLoS One.2013; 8(2):.e56418.
19. Gostry A. V., Simonova A. V., Mikhailova N. A., et al. Chronic pharyngitis: etiology, pathogenesis, treatment. New approaches to the estimation of etiopatogenesis. The Russian Archives of Internal Medicine. 2019;9(1):32–43. (in Russ.) doi: 10.20514/2226–6704–2019–9–1–32–43
20. Snimshhikova I.A., Agafonov B. V., Gostryj A. V. Clinical and diagnostic signifi cance of the method of mass spectrometry of microbial markers in the recurrent course of chronic pharyngitis. Attending doctor. 2018;(7): 58–62. (In Russ.)
21. Bagdonas E., Raudoniute J., Bruzauskaite I., et al. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J. Chron Obstruct Pulmon Dis. 2015;(10):995–1013.
22. Cuthbertson L., Craven V., Bingle L., et al. Th e impact of persistent bacterial bronchitis on the pulmonary microbiome of children. PLoS One. 2017; 12(12): e0190075.
23. Sokolowska M., Frei R., Lunjani N., et al. Microbiome and asthma. Asthma Res Pract. 2018;(4):1.
24. Carr T.F., Alkatib R., Kraft M. Microbiome in Mechanisms of Asthma. Clin Chest Med. 2019;40(1): 87–96.
25. Goleva E., Jackson L. P., Harris J. K., et al. Th e eff ects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med. 2013;(188): 1193–1201.
26. Turturice B.A., McGee H.S., Oliver B., et al. Atopic asthmatic immune phenotypes associated with airway microbiota and airway obstruction. PLoS One. 2017;12(10): e0184566.
27. Szmidt M.K., Kaluza J., Harris H. R., et al. Long-term dietary fi ber intake and risk of chronic obstructive pulmonary disease: a prospective cohort study of women. Eur J Nutr. 2019; 59(5): 1869–1879.
28. Vaughan A., Frazer Z. A., Hansbro P. M., et al. COPD and the gut-lung axis: the therapeutic potential of fi bre. J Th orac Dis. 2019; 11(17): 2173–2180.
29. Baranovsky A. Yu., Belyaev A. M., Kondrashina E. A. Morbidity and Mortality Rates from Digestive Diseases in the RF Northwestern Federal District (NWFD) and Measures to Reduce Them. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):36–46. (In Russ.) doi:10.22416/1382–4376–2019–29–1–36–46
30. Li S., Huang X. L., Sui J. Z., et al. Meta-analysis of randomized controlled trials on the effi cacy of probiotics in Helicobacter pylori eradication therapy in children. Eur. J. Pediatr. 2014; 173(2): 153–161.
31. Kazimirova A. A., Volosnikov D. K., Bahareva L. I., et al. Microbiocenosis of the stomach in chronic gastritis in children. Journal. microbiology, epidemiology and immunobiology. 2007;(2): 71–77. (In Russ.)
32. Zaharova V.V., Karzakova L. M. Th e correction of microbiocenosis in patients with ulcerous disease of the bulb of the duodenum associated with helicobacter pylori infection. Acta medica Eurasica. 2017; 2: 6–12. (In Russ.)
33. Nalyotov A. V. Th e dysbiotic changes in the intestine and the eff ectiveness of their correction in patients with chronic gastroduodenal pathology. Kursk Scientifi c and Practical Bulletin “Man and His Health”. 2015;(1):48–53. (In Russ.)
Review
For citations:
Chervinets V.M., Chervinets Yu.V., Kravchuk E.S. Intestinal imbalance in young people as a marker of chronic somatic diseases. Experimental and Clinical Gastroenterology. 2022;(4):153-159. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-200-4-153-159
Views:
204
Email this article 